Crossmark Global Holdings Inc. bought a new stake in shares of Medtronic PLC (NYSE:MDT) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 315,582 shares of the medical technology company’s stock, valued at approximately $24,543,000. Medtronic makes up 0.6% of Crossmark Global Holdings Inc.’s portfolio, making the stock its 20th biggest position.
Several other large investors have also bought and sold shares of the stock. Captrust Financial Advisors purchased a new stake in Medtronic during the 2nd quarter worth $384,000. Wesbanco Bank Inc. increased its stake in Medtronic by 3.1% during the 2nd quarter. Wesbanco Bank Inc. now owns 10,170 shares of the medical technology company’s stock worth $903,000 after buying an additional 308 shares during the period. Dupont Capital Management Corp increased its stake in Medtronic by 28.8% during the 2nd quarter. Dupont Capital Management Corp now owns 74,052 shares of the medical technology company’s stock worth $6,572,000 after buying an additional 16,562 shares during the period. Chilton Investment Co. LLC increased its stake in Medtronic by 6.1% during the 2nd quarter. Chilton Investment Co. LLC now owns 26,842 shares of the medical technology company’s stock worth $2,382,000 after buying an additional 1,538 shares during the period. Finally, Moors & Cabot Inc. increased its stake in Medtronic by 0.4% during the 2nd quarter. Moors & Cabot Inc. now owns 43,227 shares of the medical technology company’s stock worth $3,842,000 after buying an additional 178 shares during the period. Institutional investors and hedge funds own 81.85% of the company’s stock.
Medtronic PLC (MDT) opened at $81.07 on Friday. Medtronic PLC has a fifty-two week low of $69.35 and a fifty-two week high of $89.72. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.40 and a quick ratio of 2.05. The company has a market cap of $109,051.33, a PE ratio of 17.36, a PEG ratio of 2.22 and a beta of 1.00.
Medtronic (NYSE:MDT) last posted its quarterly earnings results on Tuesday, November 21st. The medical technology company reported $1.07 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.99 by $0.08. Medtronic had a net margin of 16.93% and a return on equity of 12.63%. The business had revenue of $7.05 billion during the quarter, compared to analyst estimates of $7.05 billion. During the same period in the previous year, the business posted $1.12 EPS. The company’s quarterly revenue was down 4.0% on a year-over-year basis. analysts anticipate that Medtronic PLC will post 4.77 earnings per share for the current fiscal year.
Several equities research analysts have recently weighed in on the stock. Jefferies Group dropped their target price on shares of Medtronic from $103.00 to $96.00 and set a “buy” rating for the company in a research report on Wednesday, August 23rd. Cowen set a $95.00 target price on shares of Medtronic and gave the stock a “buy” rating in a research report on Tuesday, August 22nd. Oppenheimer reissued a “buy” rating and issued a $92.00 target price on shares of Medtronic in a research report on Tuesday, August 22nd. Royal Bank Of Canada reissued a “buy” rating and issued a $90.00 target price on shares of Medtronic in a research report on Monday, August 21st. Finally, SunTrust Banks reissued a “buy” rating and issued a $96.00 target price on shares of Medtronic in a research report on Monday, October 2nd. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and thirteen have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $88.02.
In other news, EVP Bryan C. Hanson sold 16,000 shares of Medtronic stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $79.02, for a total value of $1,264,320.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Omar Ishrak sold 140,407 shares of Medtronic stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $81.63, for a total transaction of $11,461,423.41. Following the completion of the transaction, the chief executive officer now directly owns 668,503 shares of the company’s stock, valued at $54,569,899.89. The disclosure for this sale can be found here. Insiders sold a total of 172,407 shares of company stock valued at $13,974,223 over the last ninety days. Company insiders own 0.31% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2017/12/09/crossmark-global-holdings-inc-takes-position-in-medtronic-plc-mdt.html.
Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.
Receive News & Ratings for Medtronic PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic PLC and related companies with MarketBeat.com's FREE daily email newsletter.